Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5906.091 | 0.9645 | 0.8899 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5906.091 | 1.1306 | 1.4240 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5906.091 | 1.0270 | 1.0852 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5906.091 | 1.0099 | 1.0310 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5906.091 | 1.0731 | 1.2336 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5906.091 | 1.0476 | 1.1510 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5906.091 | 0.8976 | 0.6887 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5906.091 | 0.0407 | -0.9867 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5906.091 | 0.0074 | -0.9991 | 0.6385 | |
| BT-483 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5908.091 | 0.9378 | 0.7638 | 0.5109 | |
| BT-483 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5908.091 | 0.9147 | 0.6799 | 0.5109 | |
| BT-483 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5908.091 | 0.9362 | 0.7579 | 0.5109 | |
| BT-483 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5908.091 | 0.9291 | 0.7318 | 0.5109 | |
| BT-483 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5908.091 | 0.9395 | 0.7700 | 0.5109 | |
| BT-483 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5908.091 | 0.9416 | 0.7777 | 0.5109 | |
| BT-483 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5908.091 | 0.9296 | 0.7336 | 0.5109 | |
| BT-483 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5908.091 | 0.0541 | -0.9934 | 0.5109 | |
| BT-483 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5908.091 | 0.0059 | -0.9999 | 0.5109 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5909.092 | 0.9622 | 0.9748 | 3.0314 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5909.092 | 1.0517 | 1.0335 | 3.0314 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5909.092 | 1.0120 | 1.0079 | 3.0314 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5909.092 | 0.9963 | 0.9975 | 3.0314 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5909.092 | 1.0204 | 1.0134 | 3.0314 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5909.092 | 0.9288 | 0.9519 | 3.0314 | |
| BT-549 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5909.092 | 0.7853 | 0.8467 | 3.0314 |